News Release May 05, 2002 Study finds supplement users avoid prescription drugs due to side effects, not cost Brands top rated by users also identified in new survey by ConsumerLab.com WHITE PLAINS, NY March 5, 2002 ConsumerLab.com, traditionally known for its independent laboratory evaluations of dietary supplements and nutritional products, announced surprising findings today from a new survey of supplement users
For BPC-157 , the literature is almost entirely preclinical
Category 1 Bulk substance the FDA considers eligible for use in compounding pending final rulemaking Generally permitted Category 2 Bulk substance the FDA has significant safety, identity, or quality concerns about Not permitted during review Category 3 Substance requiring further evaluation Case-by-case Critically, Category 1 status is not FDA approval
You also get the full potency of the vitamins
Essential for to target dark spot or hyperpigmentation